{"id":"lecanemab-sc","safety":{"commonSideEffects":[{"rate":null,"effect":"Amyloid-related imaging abnormalities (ARIA) - microhemorrhages"},{"rate":null,"effect":"Amyloid-related imaging abnormalities (ARIA) - microinfarcts"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lecanemab targets soluble amyloid-beta protofibrils, which are believed to be toxic intermediates in Alzheimer's disease pathogenesis. By binding to these protofibrils, the antibody facilitates their removal through microglial phagocytosis and peripheral clearance. This mechanism aims to slow cognitive decline in early Alzheimer's disease by reducing amyloid burden in the brain.","oneSentence":"Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:37.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild cognitive impairment or mild dementia stage of Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT06602258","phase":"PHASE2","title":"A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-09-30","conditions":"Alzheimer's Disease","enrollment":105},{"nctId":"NCT03887455","phase":"PHASE3","title":"A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-03-27","conditions":"Early Alzheimer's Disease","enrollment":1906},{"nctId":"NCT05533801","phase":"PHASE1","title":"A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2022-09-06","conditions":"Healthy Volunteers","enrollment":160},{"nctId":"NCT05045716","phase":"PHASE1","title":"A Study of Subcutaneous Lecanemab in Healthy Participants","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-09-07","conditions":"Healthy Volunteers","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BAN2401"],"phase":"phase_3","status":"active","brandName":"Lecanemab SC","genericName":"Lecanemab SC","companyName":"Eisai Inc.","companyId":"eisai-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain. Used for Mild cognitive impairment or mild dementia stage of Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}